BridgeBio

BridgeBio is a company located in Palo Alto, United States. It describes itself as racing to develop treatments for genetic conditions, using a hub-and-spoke model in which autonomous teams focus on specific conditions or drug candidates while a central hub provides clinical, regulatory, and commercial capabilities. Its pipeline includes programs such as Acoramidis for variant transthyretin amyloidosis (ATTRv), BBP-418 for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), Encaleret for autosomal dominant hypocalcemia type 1 (ADH1), Infigratinib for achondroplasia and hypochondroplasia, and BBP-812 for Canavan disease.

• 2021-07-08

  BridgeBio announces three academic collaborations[4]BridgeBio 宣布与三家学术机构合作prnewswire.com

  Reported: 2021-07-08

  BridgeBio announced new academic collaborations with MUSC Foundation for Research Development, Stanford University and the University of Pittsburgh to identify and advance potential therapies for genetic diseases and genetically driven cancers.

• 2020-08-11

  LianBio establishes strategic relationship with BridgeBio[5]LianBio 与 BridgeBio 建立战略关系fiercebiotech.com

  Reported: 2020-08-11

  LianBio established a strategic relationship with BridgeBio that gives LianBio first dibs on 20 programs already in BridgeBio’s pipeline and on assets BridgeBio may bring under its umbrella during the following four years.

1. 1Homebridgebio.com
2. 2Aboutbridgebio.com
3. 3BridgeBiowikidata.org
4. 4BridgeBio 宣布与三家学术机构合作prnewswire.com
5. 5LianBio 与 BridgeBio 建立战略关系fiercebiotech.com
6. 6BridgeBio Pharma Announces Collaborations with Columbia University and Mount Sinai to Develop Potential Therapies for Genetic Diseases and Cancersprnewswire.com